Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial

Inclusion Criteria: * Pathologically proven gastric or gastroesophageal junction adenocarcinoma * Metastatic or recurrent unresectable disease * Measurable lesions (according to Response Evaluation Criteria in Solid Tumors \[RECIST\]) * Age: 65-85 years old * Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 * Adequate bone marrow function: absolute neutrophile counts(ANC) ≥ 1,500/ul, platelet count ≥ 100,000/ul, hemoglobin ≥ 9 g/dl) * Adequate renal function (serum creatinine≤ 1.5) * Adequate liver function (serum bilirubin ≤ 2 x upper limits of normal \[UNL\], aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x UNL) * No prior chemotherapy (but adjuvant chemotherapy completed at least 1 year prior to study treatment is allowed with the exception of capecitabine or S-1) Written informed consent was signed by the patient Exclusion Criteria: * Previous palliative chemotherapy * Known allergy to study drugs * CNS metastasis * Significant medical comorbidities * Active ongoing infection which antibiotic treatment is needed. * Previous ( within 5 years) history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ.